Atea Pharmaceuticals, Inc. Common Stock AVIR
i
Market datapartial · fetched 2026-11-11T14:01:56.387Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T21:00:08.461141326Z
FundamentalsAlpha Vantage · unavailable
Atea Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 3.74 | 427.4% | 37.8% | |||
| 25Δ | 9.07 | 453.7% | 123.7% | 4.13 | 496.8% | 36.8% |
| 30Δ | 7.36 | 406.2% | 84.4% | 4.52 | 566.1% | 35.8% |
| 35Δ | 6.49 | 359.5% | 64.3% | 4.91 | 635.5% | 34.8% |
| 40Δ | 5.61 | 312.8% | 44.3% | 5.39 | 632.9% | 32.1% |
| 45Δ | 4.91 | 296.7% | 29.9% | 5.90 | 607.1% | 28.9% |
| 50Δ | 4.61 | 351.4% | 28.4% | 6.41 | 581.2% | 25.8% |
| 55Δ | 4.30 | 406.0% | 26.9% | 6.93 | 555.4% | 22.6% |
| 60Δ | 4.00 | 460.7% | 25.4% | 7.44 | 529.6% | 19.4% |
| 65Δ | 3.70 | 515.3% | 23.8% | 7.95 | 503.8% | 16.3% |
| 70Δ | 3.40 | 570.0% | 22.3% | 8.46 | 478.0% | 13.1% |
| 75Δ | 3.09 | 624.6% | 20.8% | 8.98 | 452.2% | 9.9% |
| 80Δ | 2.79 | 679.3% | 19.3% | 9.49 | 426.4% | 6.7% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.74
- IV
- 427.4%
- B/E move
- 37.8%
25Δ
- Pseudo strike
- 9.07
- IV
- 453.7%
- B/E move
- 123.7%
- Pseudo strike
- 4.13
- IV
- 496.8%
- B/E move
- 36.8%
30Δ
- Pseudo strike
- 7.36
- IV
- 406.2%
- B/E move
- 84.4%
- Pseudo strike
- 4.52
- IV
- 566.1%
- B/E move
- 35.8%
35Δ
- Pseudo strike
- 6.49
- IV
- 359.5%
- B/E move
- 64.3%
- Pseudo strike
- 4.91
- IV
- 635.5%
- B/E move
- 34.8%
40Δ
- Pseudo strike
- 5.61
- IV
- 312.8%
- B/E move
- 44.3%
- Pseudo strike
- 5.39
- IV
- 632.9%
- B/E move
- 32.1%
45Δ
- Pseudo strike
- 4.91
- IV
- 296.7%
- B/E move
- 29.9%
- Pseudo strike
- 5.90
- IV
- 607.1%
- B/E move
- 28.9%
50Δ
- Pseudo strike
- 4.61
- IV
- 351.4%
- B/E move
- 28.4%
- Pseudo strike
- 6.41
- IV
- 581.2%
- B/E move
- 25.8%
55Δ
- Pseudo strike
- 4.30
- IV
- 406.0%
- B/E move
- 26.9%
- Pseudo strike
- 6.93
- IV
- 555.4%
- B/E move
- 22.6%
60Δ
- Pseudo strike
- 4.00
- IV
- 460.7%
- B/E move
- 25.4%
- Pseudo strike
- 7.44
- IV
- 529.6%
- B/E move
- 19.4%
65Δ
- Pseudo strike
- 3.70
- IV
- 515.3%
- B/E move
- 23.8%
- Pseudo strike
- 7.95
- IV
- 503.8%
- B/E move
- 16.3%
70Δ
- Pseudo strike
- 3.40
- IV
- 570.0%
- B/E move
- 22.3%
- Pseudo strike
- 8.46
- IV
- 478.0%
- B/E move
- 13.1%
75Δ
- Pseudo strike
- 3.09
- IV
- 624.6%
- B/E move
- 20.8%
- Pseudo strike
- 8.98
- IV
- 452.2%
- B/E move
- 9.9%
80Δ
- Pseudo strike
- 2.79
- IV
- 679.3%
- B/E move
- 19.3%
- Pseudo strike
- 9.49
- IV
- 426.4%
- B/E move
- 6.7%
Options history
No recorded observations
Biotechnology
AVLN
Description unavailable
More →AVTX
Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved diseases, particularly…
More →AVXL
Description unavailable
More →AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is…
More →BBIO
Description unavailable
More →BCAX
Description unavailable
More →